-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178

Benzinga·08/17/2026 12:49:48
Listen to the news
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.